Breast, A012301 "LOTAM"
A randomized phase III clinical trial of low-dose Tamoxifen for selected patients with molecular low-risk early-stage breast cancer.
Breast, A191901
Optimizing endocrine therapy through motivational interviewing and text interventions
Breast, ASCENT-05/ GS-US-595-6184/ AFT-65
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Breast, Cambria-2 D8535C00001
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).
Breast, CELC-G-301
Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer
Breast, NRG-BR007
DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18
Breast, OptimICE-pCR: A012103
This phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.
Breast, Ovation-23-001
The objective of this study is to establish a biorepository and database of specimens to enable future research on the role of molecular genomics in the biological mechanisms of cancers, as well as to validate measures of molecular residual disease in these patient populations.
Breast, Personalis, 01-PS-001
ClinicalTrials.gov ID NCT06230185
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Breast, STML-ELA-0422 “ELEGANT”
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.